Mergen

Mergen Biotech is a clinical-stage biotechnology company headquartered in Wuhan, China, specializing in the development of Adeno-Associated Virus (AAV) gene therapies. The company leverages its proprietary AAV vector discovery and optimization platform to create highly efficient and tissue-specific gene delivery systems for treating genetic and chronic diseases. Mergen's internal pipeline is focused on high-unmet-need areas, including ophthalmology, hematology, and the central nervous system, with its lead candidate, MG-001, targeting Leber Congenital Amaurosis. In addition to its drug development efforts, Mergen provides comprehensive CDMO services for viral vector production, utilizing its GMP-compliant manufacturing facilities. The company is backed by prominent venture capital firms such as Sequoia China and Northern Light Venture Capital.